Growing evidence suggests that when GPX4 is inactivated, FSP1 can continue to maintain tumor growth in vivo, while deletion of GPX4 and FSP1 can inhibit tumor growth (Doll et al., 2019). The gene discussed is AIFM2; the disease is neoplasm.